Dimensional Fund Advisors LP Grows Holdings in Globus Medical, Inc. $GMED

Dimensional Fund Advisors LP lifted its holdings in shares of Globus Medical, Inc. (NYSE:GMED) by 2.0% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,769,897 shares of the medical device company’s stock after acquiring an additional 33,976 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Globus Medical were worth $152,474,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Advisory Services Network LLC acquired a new stake in Globus Medical during the third quarter valued at approximately $26,000. EverSource Wealth Advisors LLC lifted its stake in Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after buying an additional 197 shares during the last quarter. SBI Securities Co. Ltd. grew its position in shares of Globus Medical by 98.2% during the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after acquiring an additional 167 shares during the last quarter. Parallel Advisors LLC increased its holdings in shares of Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after acquiring an additional 173 shares during the period. Finally, Headlands Technologies LLC increased its holdings in shares of Globus Medical by 485.4% in the 2nd quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock worth $45,000 after acquiring an additional 631 shares during the period. 95.16% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have issued reports on GMED. Wall Street Zen lowered shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Zacks Research lowered shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Truist Financial cut their price target on Globus Medical from $115.00 to $100.00 and set a “buy” rating on the stock in a report on Thursday, July 16th. Royal Bank Of Canada cut their price target on Globus Medical from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. Finally, Needham & Company LLC boosted their price objective on Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $103.75.

Insider Buying and Selling

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of Globus Medical stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the transaction, the director owned 510,175 shares of the company’s stock, valued at $41,201,733. The trade was a 4.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 18.38% of the company’s stock.

Globus Medical Stock Performance

GMED opened at $76.46 on Monday. Globus Medical, Inc. has a one year low of $51.79 and a one year high of $101.40. The company has a market capitalization of $10.38 billion, a PE ratio of 17.78, a P/E/G ratio of 1.58 and a beta of 0.95. The stock’s fifty day moving average is $79.79 and its 200-day moving average is $86.03.

Globus Medical (NYSE:GMED) last issued its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The firm had revenue of $759.85 million during the quarter, compared to analysts’ expectations of $740.35 million. During the same period last year, the firm posted $0.68 earnings per share. The firm’s revenue for the quarter was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, equities research analysts forecast that Globus Medical, Inc. will post 4.74 EPS for the current fiscal year.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.